Epilepsy is one of the most common neurological conditions, with more than 2% of the worldwide population affected, according to the latest study [1]. Patients with epilepsy need long-term or lifelong aromatic antiepileptic drugs (AEDs) [2]. Maculopapular eruption (MPE) is the most common clinical manifestation of cutaneous adverse drug reactions (cADRs) in patients taking aromatic AEDs [3]. MPE is characterized by small pink patches and papules on the skin. Clinically, the overall incidence of various forms of AED-induced cADRs is approximately 10% [4].
24
MAY
MAY
0